logo-loader

Alliance Pharma steady in latest half year

Published: 07:38 09 Jul 2014 BST

pharma_350_53bce4388b4a0

Alliance Pharma’s (LON:APH) interim results will meet expectations with sales of Hydromol and Ashton & Parsons infant powder remaining strong.

The group, which acquires mature prescription treatments no longer wanted by major pharmas, said total revenues for the six months to June were approximately £22.5mln (£22.8mln) or £21.4mln (£22.8mln) stripping out joint venture income. 

Sales of eczema cream Hydromol rose 15% to £3mln in the period, while Ashton & Parsons sales were £0.7mln compared to £0.1 mln a year ago when production capacity was an issue. 

Nu-Seals revenue declined slightly to £1.4mln (2013: £1.6mln), while recent acquisitions Lypsyl in the UK and Ireland and Irenat in Germany generated £0.5 mln and £0.4 mln respectively. 

Alliance said: “We continue to expect trading performance in 2014 to be in line with our plans, before the positive impact of any further acquisitions.

“Around £22 mln of our acquisition bank facility remains undrawn and available to fund opportunities as they arise.”

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

40 minutes ago